Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06691191 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Study acronym: SWAP-7
StatusRecruiting
PhasePhase 4
Started2025-01-08
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 5, 2026 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-02-03
Study Status v2
Re-verified, no change to tracked fields
2025-01-22
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-01-01→confirmed 2025-01-08
Study sitesdetails revised at 1 of 1 site
2024-11-14
Original filing
Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.
Trial Details
NCT Number NCT06691191
Lead Sponsor University of Florida
Conditions Coronary Artery Disease
Enrollment 48 participants
Start Date 2025-01-08
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-05